z-logo
open-access-imgOpen Access
Chemotherapy options for metastatic colorectal carcinoma: First, second, third line...
Author(s) -
Zorica Tomasevic,
S Jelić,
Davorin Radosavljević,
I Popov
Publication year - 2003
Publication title -
archive of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.104
H-Index - 13
eISSN - 1450-9520
pISSN - 0354-7310
DOI - 10.2298/aoo0303165t
Subject(s) - medicine , oxaliplatin , irinotecan , chemotherapy , colorectal cancer , oncology , first line , fluorouracil , surgical oncology , general surgery , radiology , cancer
For almost 40 years, the only option for patients with unresectable metastases was treatment with 5-fluorouracil. In the last decade, new drugs became available that changed attitude toward treatment of metastatic CRC as well as the prognosis for some patients although the "story" of 5-FU is not finished yet. Irinotecan, oxaliplatin and oral fluoropyrimidines produces higher response rates, longer symptom control and longer survival for the majority of the patients with unresectable metastases. Neoadjuvant chemotherapy is particularly interesting, because according to the results of some studies, it actually allows curative resections of previously unresectable liver metastases. This paper deals with the current status of chemotherapy of metastatic CRC, and some dilemmas about that issue. Also, we report results of third line chemotherapy of metastatic CRC patients treated at the Institute for Oncology and radiology of Serbia (IORS)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom